Issue 21, 2022

Recent advances on drug delivery nanoplatforms for the treatment of autoimmune inflammatory diseases

Abstract

As one of the current research hotspots, drug release nanoplatforms have great potential in the treatment of autoimmune inflammatory diseases. At present, most of the drugs used in clinic do not have tissue specificity and are difficult to play a full role in the treatment of diseases. Therefore, giving full play to the real efficacy of drugs is a very challenging task. The drug treatment effect has been significantly improved by designing and developing intelligent nanoplatforms to achieve drug targeting and controlled release, which can fundamentally change the treatment strategy of autoimmune inflammatory diseases. In this review, the principles of drug delivery through different action mechanisms of nanoplatforms are reviewed, with emphasis on the specific applications of nanoplatforms in various autoimmune inflammatory diseases. Moreover, the future development of nanoplatforms to further improve the efficacy of clinical drugs is also prospected.

Graphical abstract: Recent advances on drug delivery nanoplatforms for the treatment of autoimmune inflammatory diseases

Article information

Article type
Review Article
Submitted
09 iyl 2022
Accepted
01 sen 2022
First published
12 sen 2022
This article is Open Access
Creative Commons BY license

Mater. Adv., 2022,3, 7687-7708

Recent advances on drug delivery nanoplatforms for the treatment of autoimmune inflammatory diseases

J. Zhu, W. Chen, Y. Sun, X. Huang, R. Chu, R. Wang, D. Zhou and S. Ye, Mater. Adv., 2022, 3, 7687 DOI: 10.1039/D2MA00814A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements